Alvea, launched as an "EA Covid Vaccine Project", set the record for being the Fastest Startup to Take a New Drug into a Phase 1 Clinical Trial according to their website. Compared to other drugs, vaccines have a high baseline probability of reaching the market, conditional on entering Phase 1 Clinical Trials - around 33% of candidates are eventually approved. Usually, it takes more than 10 years for a new drug to reach the market. The BioNTech/Pfizer vaccine took around 8 months from the first trials to be approved for emergency use in some countries. Will Alvea be able to bring a product to the market in only five years?

Alvea says its first (and so far only) drug candidate, a plasmid DNA Omicron variant-optimized COVID-19 booster vaccine, was conceived on Dec 16th 2021. This market will resolves to YES if a compound primarily developed by Alvea is approved for marketing or emergency use by the FDA or EMA by Dec 31 2026. If a compound reaches the market, which was sold by Alvea or is developed in a partnership, the market resolves to YES if the compound originated at Alvea according to the respective companies or other trustworthy sources.

Close date updated to 2026-12-31 11:59 pm